tLNP
RiboX Enters Crowded In Vivo CAR-T Field With FDA IND Nod
RiboX Therapeutics Ltd., a private, clinical-stage biotechnology company with operations in China, the U.S., and Israel, announced on August 8 that the FDA has cleared its Investigational New Drug (IND) application for RXIM002, clearing the way for a Phase 1 trial of what the company describes as the first circular RNA-based in vivo CAR-T therapy…
